In addition, in a preclinical model of breast cancer, combination of AXL suppression and anti-PD-1 resulted in both primary and metastatic tumor shrinkage, increased CD8T cell infiltration, and an increased rate of NK cell activation (90), which could not be achieved after treatment with either drug alone. Here, AXL is linked to breast cancer.